This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2009 Dec;19(12):979-83.

doi: 10.1097/FPC.0b013e3283335277.

Taxane pathway

Connie Oshiro¹, Sharon Marsh, Howard McLeod, Michelle Whirl Carrillo, Teri Klein, Russ Altman

Affiliations

PMID: 21151855
PMCID: PMC2998989
DOI: 10.1097/FPC.0b013e3283335277

Taxane pathway

Connie Oshiro et al. Pharmacogenet Genomics. 2009 Dec.

. 2009 Dec;19(12):979-83.

doi: 10.1097/FPC.0b013e3283335277.

Authors

Connie Oshiro¹, Sharon Marsh, Howard McLeod, Michelle Whirl Carrillo, Teri Klein, Russ Altman

Affiliation

¹ Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada.

PMID: 21151855
PMCID: PMC2998989
DOI: 10.1097/FPC.0b013e3283335277

No abstract available

PubMed Disclaimer

Figures

Fig.1 — Fig.1
Representation of known candidate genes involved in the pharmacokinetics and pharmacodynamics of taxanes.

See this image and copyright information in PMC

Similar articles

The taxoids: paclitaxel and docetaxel.
Gelmon K. Gelmon K. Lancet. 1994 Nov 5;344(8932):1267-72. doi: 10.1016/s0140-6736(94)90754-4. Lancet. 1994. PMID: 7967989 Review. No abstract available.
Docetaxel in the management of ovarian cancer.
Blagden SP, Kaye SB. Blagden SP, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):203-14. doi: 10.1586/14737140.5.2.203. Expert Rev Anticancer Ther. 2005. PMID: 15877518 Review.
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Engels FK, Sparreboom A, Mathot RA, Verweij J. Engels FK, et al. Br J Cancer. 2005 Jul 25;93(2):173-7. doi: 10.1038/sj.bjc.6602698. Br J Cancer. 2005. PMID: 16012521 Free PMC article. Review.
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A. Acharya MR, et al. Anal Biochem. 2004 Aug 1;331(1):192-4. doi: 10.1016/j.ab.2004.03.045. Anal Biochem. 2004. PMID: 15246014 No abstract available.
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Hortobagyi GN, Kris MG. Hortobagyi GN, et al. Semin Oncol. 2002 Jun;29(3 Suppl 12):1-3. doi: 10.1053/sonc.2002.34253. Semin Oncol. 2002. PMID: 12170444 Review. No abstract available.

See all similar articles

Cited by

Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Krens SD, McLeod HL, Hertz DL. Krens SD, et al. Pharmacogenomics. 2013 Apr;14(5):555-74. doi: 10.2217/pgs.13.33. Pharmacogenomics. 2013. PMID: 23556452 Free PMC article.
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Chhibber A, et al. Pharmacogenomics J. 2014 Aug;14(4):336-42. doi: 10.1038/tpj.2014.2. Epub 2014 Feb 11. Pharmacogenomics J. 2014. PMID: 24513692 Free PMC article. Clinical Trial.
Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.
Gatti DM, Weber SN, Goodwin NC, Lammert F, Churchill GA. Gatti DM, et al. Pharmacogenomics J. 2018 Apr;18(2):319-330. doi: 10.1038/tpj.2017.23. Epub 2017 Jun 13. Pharmacogenomics J. 2018. PMID: 28607509 Free PMC article.
Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.
Weissfeld JL, Diergaarde B, Nukui T, Buch S, Pennathur A, Socinski MA, Siegfried JM, Romkes M. Weissfeld JL, et al. J Thorac Oncol. 2014 Sep;9(9):1264-71. doi: 10.1097/JTO.0000000000000262. J Thorac Oncol. 2014. PMID: 25122423 Free PMC article.
circRNAs in drug resistance of breast cancer.
Misir S, Yaman SO, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. Misir S, et al. Oncol Res. 2023 Jan 31;30(4):157-172. doi: 10.32604/or.2022.027547. eCollection 2022. Oncol Res. 2023. PMID: 37304411 Free PMC article. Review.

See all "Cited by" articles

References

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–265. - PubMed
1. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 2:3–8. - PubMed
1. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132. - PubMed
1. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. Taxanes: a new class of antitumor agents. Cancer Invest. 1995;13:381–404. - PubMed
1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

U01 GM061374/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources